- Home
- XPER vs ALT Comparison
XPER vs ALT Comparison
Compare XPER & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPER
- ALT
- Stock Information
- Founded
- XPER 1990
- ALT 1997
- Country
- XPER United States
- ALT United States
- Employees
- XPER N/A
- ALT N/A
- Industry
- XPER Semiconductors
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- XPER Technology
- ALT Health Care
- Exchange
- XPER Nasdaq
- ALT Nasdaq
- Market Cap
- XPER 304.4M
- ALT 348.6M
- IPO Year
- XPER 2003
- ALT N/A
- Fundamental
- Price
- XPER $5.44
- ALT $4.44
- Analyst Decision
- XPER Strong Buy
- ALT Strong Buy
- Analyst Count
- XPER 2
- ALT 7
- Target Price
- XPER $11.00
- ALT $16.33
- AVG Volume (30 Days)
- XPER 486.2K
- ALT 3.1M
- Earning Date
- XPER 11-05-2025
- ALT 11-06-2025
- Dividend Yield
- XPER N/A
- ALT N/A
- EPS Growth
- XPER N/A
- ALT N/A
- EPS
- XPER 0.15
- ALT N/A
- Revenue
- XPER $453,960,000.00
- ALT $20,000.00
- Revenue This Year
- XPER N/A
- ALT N/A
- Revenue Next Year
- XPER $6.47
- ALT N/A
- P/E Ratio
- XPER $35.47
- ALT N/A
- Revenue Growth
- XPER N/A
- ALT N/A
- 52 Week Low
- XPER $5.40
- ALT $2.90
- 52 Week High
- XPER $11.08
- ALT $10.88
- Technical
- Relative Strength Index (RSI)
- XPER 26.67
- ALT 60.74
- Support Level
- XPER $6.40
- ALT $3.95
- Resistance Level
- XPER $6.70
- ALT $4.75
- Average True Range (ATR)
- XPER 0.30
- ALT 0.26
- MACD
- XPER -0.13
- ALT 0.05
- Stochastic Oscillator
- XPER 0.00
- ALT 71.57
About XPER Xperi Inc.
Xperi Inc is a consumer and entertainment technology company. Its offering comprises a portfolio of software and services. The company creates extraordinary experiences at home and on the go for millions of consumers around the world, enabling audiences to connect with content in a more intelligent, immersive, and personal way. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment. Its also have sales in Japan, Europe and Middle East, China, South Korea, Latin America, and Others.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.